ALDH2 is not only tightly associated with the activation and inhibition of cancer pathways, but also displays a predominant correlation with the sensitivity and resistance of multiple drugs, and has the best prediction efficacy in assessing immunotherapeutic response compared with CD8, CTLA4, PD-1, PD-L1, and TMB in SCKM. This evidence concerns the gene ALDH2 and cancer.